Halozyme Therapeutics HALO Convertible Preferred Stock Authorized Shares
Convertible Preferred Stock Authorized Shares at other companies
Other financials
Where this comes from
Reported directly by Halozyme Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:PreferredStockSharesAuthorized.
The official record: Halozyme Therapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about Halozyme Therapeutics's convertible preferred stock authorized shares.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Halozyme Therapeutics's convertible preferred stock authorized shares?
- Halozyme Therapeutics (HALO) reported convertible preferred stock authorized shares of 20M in Q1 2026.
- How has Halozyme Therapeutics's convertible preferred stock authorized shares changed year-over-year?
- Halozyme Therapeutics's convertible preferred stock authorized shares decreased by 0.0% year-over-year, from 20M to 20M.
- What is the long-term trend for Halozyme Therapeutics's convertible preferred stock authorized shares?
- Over 5 years (2020 to 2025), Halozyme Therapeutics's convertible preferred stock authorized shares has grown at a 0.0% compound annual growth rate (CAGR), from 20M to 20M.
- What does convertible preferred stock authorized shares mean?
- Maximum number of convertible preferred shares the company is authorized to issue under its corporate charter.